1.58

5.39% -0.09

After Hours: 1.61 0.03 +1.90%

Ovid Therapeutics Inc (OVID)

Overview News Price History Option Chain Financials Discussions Forecast

Ovid Therapeutics Inc stock is traded at $1.58, with a volume of 1.95M. It is down -5.39% in the last 24 hours and up +25.40% over the past month. Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Previous Close:

$1.67

Open:

$1.72

24h Volume:

1.95M

Relative Volume:

0.64

Market Cap:

$112.35M

Revenue:

$391.70K

Net Income/Loss:

$-52.34M

P/E Ratio:

-2.1067

EPS:

-0.75

Net Cash Flow:

$-45.92M

1W Performance:

-11.73%

1M Performance:

+25.40%

6M Performance:

+464.29%

1Y Performance:

+37.39%

1-Day Range:

$1.57

$1.72

1-Week Range:

$1.57

$1.86

52-Week Range:

$0.2425

$2.01

Ovid Therapeutics Inc Stock (OVID) Company Profile

Name

Ovid Therapeutics Inc

Sector

Healthcare (1142)

Industry

Biotechnology (637)

Phone

212-776-4381

Address

441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY

Employee

Twitter

@OvidRx

Next Earnings Date

2024-11-04

Latest SEC Filings

OVID's Discussions on Twitter

Compare OVID with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OVID Ovid Therapeutics Inc	1.58	118.75M	391.70K	-52.34M	-45.92M	-0.75
VRTX Vertex Pharmaceuticals Inc	407.37	104.55B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	464.95	60.36B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	557.73	59.84B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	799.56	49.07B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	327.03	35.16B	4.56B	-176.77M	225.30M	-1.7177

Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-25	Initiated	Oppenheimer	Outperform
Aug-08-25	Resumed	B. Riley Securities	Buy
Jun-18-24	Downgrade	Oppenheimer	Outperform → Perform
Apr-30-24	Initiated	B. Riley Securities	Buy
Apr-29-24	Initiated	H.C. Wainwright	Buy
Apr-05-24	Initiated	Wedbush	Outperform
Dec-21-23	Initiated	BTIG Research	Buy
Oct-13-23	Initiated	Oppenheimer	Outperform
Apr-20-21	Downgrade	Cantor Fitzgerald	Buy → Neutral
Mar-03-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-02-20	Downgrade	Citigroup	Buy → Neutral
Dec-02-20	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-19	Initiated	RBC Capital Mkts	Outperform
Apr-20-18	Initiated	Ladenburg Thalmann	Buy

View All

Ovid Therapeutics Inc Stock (OVID) Latest News

11:00 AM

Combining machine learning predictions for Ovid Therapeutics Inc.2025 Volatility Report & Consistent Growth Stock Picks - newser.com

11:00 AM

09:45 AM

Is a relief rally coming for Ovid Therapeutics Inc. holders2025 Short Interest & Community Verified Trade Signals - newser.com

09:45 AM

Oct 12, 2025

Is Ovid Therapeutics Inc. (1OT) stock protected from inflationMarket Performance Summary & Verified Technical Signals - newser.com

Oct 12, 2025

Oct 10, 2025

OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - Yahoo Finance

Oct 10, 2025

Oppenheimer Initiates Coverage on Ovid Therapeutics (NASDAQ:OVID) - MarketBeat

Oct 10, 2025

Ovid Therapeutics' (OVID) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat

Oct 10, 2025

Will Ovid Therapeutics Inc. benefit from macro trendsWeekly Profit Summary & Long Hold Capital Preservation Tips - newser.com

Oct 10, 2025

Real time pattern detection on Ovid Therapeutics Inc. stock2025 Bull vs Bear & Short-Term Trading Alerts - newser.com

Oct 10, 2025

Ovid Therapeutics Inc Stock Analysis and ForecastStock Rotation Strategies & Exceptional Trading Strategies - earlytimes.in

Oct 10, 2025

Market reaction to Ovid Therapeutics Inc.’s recent newsRate Hike & Breakout Confirmation Alerts - newser.com

Oct 10, 2025

Oct 09, 2025

Ovid spikes as Wedbush moves to Outperform on lead asset - MSN

Oct 09, 2025

Ovid Therapeutics (OVID) Surges on Positive Analyst Rating - GuruFocus

Oct 09, 2025

Ovid Therapeutics' OV329 Shows Promise as Epilepsy Treatment, Oppenheimer Says - MarketScreener

Oct 09, 2025

Technical signs of recovery in Ovid Therapeutics Inc.IPO Watch & Risk Controlled Swing Alerts - newser.com

Oct 09, 2025

What data driven models say about Ovid Therapeutics Inc.’s futureWeekly Risk Report & High Yield Equity Trading Tips - newser.com

Oct 09, 2025

What drives PSP Swiss Property AG Common Stock P7S0 stock priceCapital Gains Strategies & Follow Top Performers in the Community - earlytimes.in

Oct 09, 2025

Is Ovid Therapeutics Inc. (1OT) stock vulnerable to rate hikesJuly 2025 Retail & Capital Efficiency Focused Ideas - newser.com

Oct 09, 2025

Detecting price anomalies in Ovid Therapeutics Inc. with AITrade Volume Report & Real-Time Buy Zone Alerts - newser.com

Oct 09, 2025

Tools to assess Ovid Therapeutics Inc.’s risk profileEarnings Growth Summary & Weekly Chart Analysis and Guides - newser.com

Oct 09, 2025

Oct 07, 2025

Hudson Yards seizure drug company raises $81M after cutting expenses - Crain's New York Business

Oct 07, 2025

What analysts say about Ovid Therapeutics Inc 1OT stockStock Rotation Strategies & Minimal Capital Investment - earlytimes.in

Oct 07, 2025

Ovid Therapeutics (OVID): Evaluating Valuation After Positive Phase 1 Trial Results and $175 Million Financing - Sahm

Oct 07, 2025

Oct 06, 2025